# Risk of intracranial haemorrhage in patients with acute ischaemic stroke and prior antiplatelet therapy

**Authors:** Lukas Nussbaum, Sabine Schaedelin, Leo Bonati, Marcel Arnold, David J Seiffge, Martina Goeldlin, Stefan Engelter, Alexandros A Polymeris, Timo Kahles, Krassen Nedeltchev, Georg Kägi, Davide Strambo, Alexander Salerno, Emmanuel Carrera, Susanne Wegener, Carlo Cereda, Manuel Bolognese, Lehel-Barna Lakatos, Andrea Humm, Friedrich Medlin, Nils Peters, Dennis Thumm, Sylvan Albert, Maria Ligon, Christian Berger, Marie-Luise Mono, Susanne Renaud, Julien Niederhauser, Alexander Tarnutzer, Nicole Bruni, Mira Katan, Gian Marco De Marchis, Philippe Lyrer

PMC · DOI: 10.1093/esj/23969873251369755 · European Stroke Journal · 2026-01-01

## TL;DR

This study found that patients with no prior antiplatelet therapy had a lower risk of bleeding after stroke compared to those on single antiplatelet therapy.

## Contribution

The study provides new evidence on the risk of intracranial hemorrhage in stroke patients based on prior antiplatelet therapy usage.

## Key findings

- Patients with no prior antiplatelet therapy had a decreased risk of symptomatic intracranial hemorrhage compared to those on single antiplatelet therapy.
- Dual antiplatelet therapy was associated with higher risk of recurrent ischaemic stroke and worse functional outcomes.
- Most intracranial hemorrhages occurred within the first days after admission.

## Abstract

Whether patients with acute ischaemic stroke (AIS) and prior antiplatelet therapy (APT) are at higher risk of symptomatic intracranial haemorrhage (sICH) has not been established. This study aimed to determine whether prior APT increases the risk of bleeding.

41,113 patients treated for AIS in Switzerland between 2014 and 2022 were analysed. The primary outcome was sICH, and secondary outcomes were recurrent ischaemic stroke (IS), all-cause mortality, functional outcome at discharge and 90 days. Patients grouped by prior APT: no APT (nAPT), single APT (SAPT), and dual APT (DAPT) were analysed using logistic and Cox proportional hazards regression. Confounding variables, including revascularisation treatment, were accounted for using multivariable adjustment and matching, and a time-to-event analysis was performed.

In the adjusted analysis at 90 days, patients with nAPT versus SAPT had a decreased risk of sICH (aOR 0.75 (0.62–0.90), p < 0.01), while these occurred within the first days. There was no difference in the risk of recurrent IS, all-cause mortality, or functional outcome. Patients with DAPT had no higher risk of sICH or mortality than those with SAPT, but a higher occurrence of recurrent IS (aOR 1.41 (1.12–1.77), p < 0.01) and worse functional outcome (aOR 1.18 (1.07–1.31), p < 0.01). The results were consistent after adjusting for revascularisation treatment.

Patients with nAPT had a lower risk of sICH than those with SAPT. Patients with DAPT have a higher risk of recurrent IS and worse functional outcome respectively. The majority of sICH occurred within the first days after admission.

Graphical Abstract

## Linked entities

- **Diseases:** ischaemic stroke (MONDO:1060198)

## Full-text entities

- **Diseases:** IS (MESH:D002544), AIS (MESH:D020521), bleeding (MESH:D006470), intracranial haemorrhage (MESH:D013345)
- **Chemicals:** antiplatelet (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866221/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866221/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866221/full.md

---
Source: https://tomesphere.com/paper/PMC12866221